Evolution of orphan drug – Healthcare Economist
A study of Fermaglich and Miller (2023) evaluated trends in orphan drug designations and approvals after the Orphan Drug Act of 1983 was approved in the US. The authors use FDA data to evaluate between 1983 and 2022 and find that: During the 40 years